Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Molindone hydrochloride
Drug ID BADD_D01488
Description An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to moderate affinity for cholinergic and alpha-adrenergic receptors. Some electrophysiologic data from animals indicate that molindone has certain characteristics that resemble those of clozapine. (From AMA Drug Evaluations Annual, 1994, p283)
Indications and Usage Molindone is used for the management of the manifestations of psychotic disorders.
Marketing Status approved
ATC Code N05AE02
DrugBank ID DB01618
KEGG ID D00796
MeSH ID D008972
PubChem ID 9883259
TTD Drug ID D03AJF
NDC Product Code 42973-126; 42806-338; 42806-337; 14096-126; 42806-336
UNII 1DWS68PNE6
Synonyms Molindone | Moban | Molindone Hydrochloride | Hydrochloride, Molindone | Molindone Monohydrochloride | Monohydrochloride, Molindone
Chemical Information
Molecular Formula C16H25ClN2O2
CAS Registry Number 15622-65-8
SMILES CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Akathisia17.01.02.002; 19.06.02.006--
Amenorrhoea05.05.01.002; 21.01.02.001--
Blood glucose abnormal13.02.02.008---
Blood urea abnormal13.13.01.005---
Constipation07.02.02.001--
Depression19.15.01.001--
Dermatitis23.03.04.002---
Dry mouth07.06.01.002--
Dystonia17.01.03.001---
Euphoric mood19.04.02.006--
Extrapyramidal disorder17.01.02.007--
Galactorrhoea05.03.04.002; 21.05.02.002---
Gynaecomastia05.05.02.003; 21.05.04.003--
Hepatic function abnormal09.01.02.001---
Hypotension24.06.03.002--
Lenticular opacities06.06.01.003---
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001---
Libido increased19.08.03.002; 21.03.02.007--
Menstruation irregular05.05.01.008; 21.01.01.005--
Nausea07.01.07.001--
Parkinsonism17.01.05.003---
Psychomotor hyperactivity17.01.02.011; 19.11.02.003---
Salivary hypersecretion07.06.01.009---
Somnolence17.02.04.006; 19.02.05.003--
Tachycardia02.03.02.007---
Tardive dyskinesia17.01.02.012---
Thyroid function test abnormal13.10.06.001---
Urinary retention20.02.02.011--
Vision blurred06.02.06.007; 17.17.01.010--
The 1th Page    1 2    Next   Last    Total 2 Pages